Vetoryl 20 mg 20 mg Capsule is a Health Canada–registered veterinary drug (DIN 02551276) held by Dechra Ltd, containing Trilostane. Health Canada lists its status as Marketed (status date 11 Feb 2025). Nexara Health has matched 28 registrations of Trilostane across 6 other regulated markets.
Health Canada registration
| DIN | 02551276 |
|---|---|
| Brand name | Vetoryl 20 mg |
| Active ingredient | Trilostane |
| Strength | 20 mg |
| Dosage form | Capsule |
| Route | Oral |
| Company | Dechra Ltd |
| Status | Marketed — 11 Feb 2025 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Trilostane registered in other markets
28 registrations of the same molecule in 6 national registries outside Canada (first 24 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| European Union (EMA) | Trilocur | — | Authorised | EMA centrally authorised | ||
| European Union (EMA) | Trilorale | — | Authorised | EMA centrally authorised | ||
| Iceland | Trilocur | Fána - óskráð lyf | 50 mg/ml | stl | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Fána - óskráð lyf | 10 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Distica - óskráð lyf | 30 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Dýraheilsa- óskráð lyf | 60 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Dýraheilsa- óskráð lyf | 5 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Dýraheilsa- óskráð lyf | 10 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Dýraheilsa- óskráð lyf | 30 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Vetoryl | Fána - óskráð lyf | 5 mg | hylki | 0 | Lyfjastofnun lyfjaverdskra |
| Poland | Trilocur | Emdoka | 10 mg/g | Zawiesina doustna | Bezterminowe | URPL RPL |
| Poland | Trilorale | Axience | 10 mg/ml | Zawiesina doustna | Bezterminowe | URPL RPL |
| Taiwan | Modrenal Capsules | Winthrop Lab. Production Div. Of Sterling-Winthrop Group Ltd. | 膠囊劑 | 已註銷 | TFDA | |
| Taiwan | Triwinol Capsules | Winthrop Lab. Production Div. Of Sterling-Winthrop Group Ltd. | 膠囊劑 | 已註銷 | TFDA | |
| United Kingdom | Trilostane 120mg capsules | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Trilostane 60mg capsules | — | 0001 | NHS dm+d VMP | ||
| United States | Trilostane | Henan Lihua Pharmaceutical Co Ltd | Powder | FDA NDC | ||
| United States | Trilostane | Tianjin Pacific Chemical & Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Trilostane | Medisca Inc. | Powder | FDA NDC | ||
| United States | Trilostane | Tianjin Tianyao Pharmaceuticals Co., Ltd. | Powder | FDA NDC | ||
| United States | Trilostane | Professional Compounding Centers of America | Powder | FDA NDC | ||
| United States | Trilostane | Kalchem International Inc | Powder | FDA NDC | ||
| United States | Trilostane | Sterling Spa | Powder | FDA NDC | ||
| United States | Trilostane | Symbiotica Speciality Ingredients Sdn.bhd | Powder | FDA NDC |
See every manufacturer of Trilostane worldwide →
Regulator price references for Trilostane
Published list or reimbursement prices for Trilostane presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Iceland | Vetoryl | 5mg | pakki | 5,525.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 5mg | pakki | 5,781.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 10mg | pakki | 5,813.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 10mg | pakki | 5,814.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 10mg | pakki | 7,044.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 30mg | pakki | 7,645.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 30mg | pakki | 9,504.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 30mg | pakki | 10,182.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 30mg | pakki | 10,207.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Trilocur | 50mg/1ml | stk | 11,818.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 60mg | pakki | 11,897.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Vetoryl | 60mg | pakki | 11,897.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
Marketed Canadian products with the same active ingredient
| DIN | Product | Company | Strength | Form |
|---|---|---|---|---|
| 02322005 | Vetoryl 10 mg | Dechra Ltd | 10 mg | Capsule |
| 02322056 | Vetoryl 120 mg | Dechra Ltd | 120 mg | Capsule |
| 02322021 | Vetoryl 30 mg | Dechra Ltd | 30 mg | Capsule |
| 02457415 | Vetoryl 5 mg | Dechra Ltd | 5 mg | Capsule |
| 02322048 | Vetoryl 60 mg | Dechra Ltd | 60 mg | Capsule |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Vetoryl 20 mg (DIN 02551276) marketed in Canada?
Yes. Health Canada lists DIN 02551276 as Marketed as of 11 Feb 2025.
Who holds the Canadian licence for this product?
Dechra Ltd is the company of record in the Health Canada Drug Product Database.
Is Trilostane registered outside Canada?
Yes — Nexara Health has matched 28 registrations in 6 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02551276, status date 2025-02-11; national medicine registries: EMA centrally authorised, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, TFDA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02551276, status date 2025-02-11; national medicine registries: EMA centrally authorised, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, TFDA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra.
Health Canada Drug Product Database (DPD), DIN 02551276, status date 2025-02-11; national medicine registries: EMA centrally authorised, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, TFDA, URPL RPL; price sources: Lyfjastofnun lyfjaverdskra. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.